Wenli Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenli Chen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- C.-X. Liu
Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China
1 shared publication Cai-Xia Peng
Department of Pathology, Wuhan Central Hospital, Wuhan, 430014, China
1 shared publicationChangxuan Liu
Division of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
1 shared publicationDan Lv
Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology
1 shared publication- Fan Zhu
Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Fen Ai
Department of Emergency Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
1 shared publication
Latest Publications
- Open Access
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1815153
Prognostic value of the aggregate index of systemic inflammation and controlling nutritional status score for all-cause mortality in patients undergoing maintenance hemodialysis: a retrospective cohort study
Background: This study investigated the prognostic relevance of the Controlling Nutritional Status (CONUT) score and the Aggregate Index of Systemic Inflammation (AISI) for predicting all-cause mortality (ACM) in patients undergoing maintenance hemodialysis (MHD). Furthermore, the study aimed to identify independent prognostic indicators to aid clinical risk categorization and tailored therapeutic interventions. Methods: A retrospective cohort study was performed with a follow-up duration of 5 years. Extensive demographic data and clinical laboratory results were gathered, and patients were followed until December 2024, with ACM set as the principal endpoint. The predictive capabilities of the CONUT score and AISI for ACM among MHD patients were evaluated by receiver operating characteristic (ROC) curve analysis. Survival outcomes were depicted through Kaplan–Meier curves, and Cox proportional hazards regression was utilized to ascertain significant prognostic factors for five-year ACM. Results: In total, 614 patients on MHD were enrolled. ROC analysis yielded areas under the curve (AUC) of 0.704 for the CONUT score and 0.694 for AISI, with optimal threshold values identified at 3.5 and 306.100, respectively. Patients exhibiting AISI below 306.100 had markedly better cumulative survival rates ( χ 2 = 48.085, p < 0.001). Similarly, patients with CONUT scores equal to or greater than 3.5 displayed significantly reduced cumulative survival compared to those scoring below 3.5 ( χ 2 = 65.147, p < 0.001). Multivariate Cox regression analyses demonstrated that central venous catheter (CVC) utilization, CONUT score ≥ 3.5, AISI ≥ 306.100, and elevated aspartate aminotransferase (AST) levels were independently associated with increased five-year ACM ( p < 0.05). Conversely, being female and exhibiting elevated concentrations of hemoglobin (HGB), urea, and creatinine were protective against mortality ( p < 0.05). Conclusion: Both AISI and the CONUT score provide significant prognostic information for predicting ACM in patients undergoing MHD. Their combined use constitutes a robust, accessible tool for identifying high-risk individuals in this population.
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1815153
Open AccessPrognostic value of the aggregate index of systemic inflammation and controlling nutritional status score for all-cause mortality in patients undergoing maintenance hemodialysis: a retrospective cohort study
Background: This study investigated the prognostic relevance of the Controlling Nutritional Status (CONUT) score and the Aggregate Index of Systemic Inflammation (AISI) for predicting all-cause mortality (ACM) in patients undergoing maintenance hemodialysis (MHD). Furthermore, the study aimed to identify independent prognostic indicators to aid clinical risk categorization and tailored therapeutic interventions. Methods: A retrospective cohort study was performed with a follow-up duration of 5 years. Extensive demographic data and clinical laboratory results were gathered, and patients were followed until December 2024, with ACM set as the principal endpoint. The predictive capabilities of the CONUT score and AISI for ACM among MHD patients were evaluated by receiver operating characteristic (ROC) curve analysis. Survival outcomes were depicted through Kaplan–Meier curves, and Cox proportional hazards regression was utilized to ascertain significant prognostic factors for five-year ACM. Results: In total, 614 patients on MHD were enrolled. ROC analysis yielded areas under the curve (AUC) of 0.704 for the CONUT score and 0.694 for AISI, with optimal threshold values identified at 3.5 and 306.100, respectively. Patients exhibiting AISI below 306.100 had markedly better cumulative survival rates ( χ 2 = 48.085, p < 0.001). Similarly, patients with CONUT scores equal to or greater than 3.5 displayed significantly reduced cumulative survival compared to those scoring below 3.5 ( χ 2 = 65.147, p < 0.001). Multivariate Cox regression analyses demonstrated that central venous catheter (CVC) utilization, CONUT score ≥ 3.5, AISI ≥ 306.100, and elevated aspartate aminotransferase (AST) levels were independently associated with increased five-year ACM ( p < 0.05). Conversely, being female and exhibiting elevated concentrations of hemoglobin (HGB), urea, and creatinine were protective against mortality ( p < 0.05). Conclusion: Both AISI and the CONUT score provide significant prognostic information for predicting ACM in patients undergoing MHD. Their combined use constitutes a robust, accessible tool for identifying high-risk individuals in this population.
- Open Access
- 26 August 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Association between statin therapy and incident diabetes mellitus in patients with nephrotic syndrome: a retrospective cohort study
The use of statins and other lipid-lowering therapies for nephrotic syndrome (NS) patients with dyslipidemia remains controversial. This study aimed to evaluate the impact of long-term statin therapy on the risk of developing diabetes mellitus (DM) in patients with NS. A retrospective cohort study was conducted from January 2018 to December 2024. The association between statin use and the incidence of diabetes was evaluated using Cox proportional hazards regression. Restricted cubic splines were utilized to investigate potential nonlinear relationships between cumulative statin dose and diabetes risk. Subgroup analyses were performed according to age, sex, corticosteroid use, and other relevant clinical factors to assess possible effect modification. A total of 837 eligible NS patients were enrolled in this study, among whom 84 (10.03%) developed DM. Statin use significantly increased the risk of incident diabetes (HR 3.68, 95% CI: 1.95–6.94, p < 0.001), an association which remained significant after multivariable adjustment (HR 3.00, 95% CI: 1.40–6.43, p = 0.005). Higher risk was particularly evident among older patients (≥ 55 years), those with hypertension, corticosteroid non-users, and patients with BMI ≥ 28. A restricted cubic spline analysis indicated a nonlinear relationship between cumulative statin dose and diabetes risk, peaking at cumulative doses of approximately 8,000–13,000 mg and declining thereafter. Statin therapy independently predicts an elevated risk of diabetes among patients with nephrotic syndrome. This relationship exhibits dose-dependent nonlinear characteristics, suggesting careful consideration of cumulative statin dose is warranted when managing lipid disorders in this patient population.
- 26 August 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Open AccessAssociation between statin therapy and incident diabetes mellitus in patients with nephrotic syndrome: a retrospective cohort study
The use of statins and other lipid-lowering therapies for nephrotic syndrome (NS) patients with dyslipidemia remains controversial. This study aimed to evaluate the impact of long-term statin therapy on the risk of developing diabetes mellitus (DM) in patients with NS. A retrospective cohort study was conducted from January 2018 to December 2024. The association between statin use and the incidence of diabetes was evaluated using Cox proportional hazards regression. Restricted cubic splines were utilized to investigate potential nonlinear relationships between cumulative statin dose and diabetes risk. Subgroup analyses were performed according to age, sex, corticosteroid use, and other relevant clinical factors to assess possible effect modification. A total of 837 eligible NS patients were enrolled in this study, among whom 84 (10.03%) developed DM. Statin use significantly increased the risk of incident diabetes (HR 3.68, 95% CI: 1.95–6.94, p < 0.001), an association which remained significant after multivariable adjustment (HR 3.00, 95% CI: 1.40–6.43, p = 0.005). Higher risk was particularly evident among older patients (≥ 55 years), those with hypertension, corticosteroid non-users, and patients with BMI ≥ 28. A restricted cubic spline analysis indicated a nonlinear relationship between cumulative statin dose and diabetes risk, peaking at cumulative doses of approximately 8,000–13,000 mg and declining thereafter. Statin therapy independently predicts an elevated risk of diabetes among patients with nephrotic syndrome. This relationship exhibits dose-dependent nonlinear characteristics, suggesting careful consideration of cumulative statin dose is warranted when managing lipid disorders in this patient population.
- Open Access
- 25 May 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (5)
Effect of surgery for encapsulating peritoneal sclerosis on mortality in patients undergoing peritoneal dialysis: A meta-analysis
Objective: This study aimed to evaluate the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Methods: A comprehensive search using PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, and CNKI databases was conducted to extract relevant data based on predefined inclusion criteria. RevMan5.2 was applied to analyze and compare the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Results: A total of 7 studies involving 70 surgical and 57 nonsurgical patients were included, with 61.4% females and 38.6% males. Among them, 69 were Asian and 58 were European patients, with 37.7% and 75.9% of Asian and European patients accepting surgical treatment, respectively. Pooled data analysis indicated that surgical treatment was associated with significantly lower mortality than nonsurgical treatment in patients with encapsulating peritoneal sclerosis (odds ratio = 0.25, 95% confidence interval: 0.11–0.57, Z = 3.29; P = 0.001). Subgroup analysis revealed that Asian patients who accepted surgical treatment had significantly lower mortality than those receiving nonsurgical treatment (odds ratio = 0.19, 95% confidence interval: 0.06–0.57, Z = 2.93; P = 0.003), whereas no significant difference was observed in mortality between surgical and nonsurgical treatments in European patients (odds ratio = 0.38, 95% confidence interval: 0.10–1.41, Z = 1.45; P = 0.15). Conclusions: Surgical treatment was associated with reduced mortality in patients with encapsulating peritoneal sclerosis compared with nonsurgical treatment; however, this benefit was more significant in Asian patients than in European patients.
- 25 May 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (5)
Open AccessEffect of surgery for encapsulating peritoneal sclerosis on mortality in patients undergoing peritoneal dialysis: A meta-analysis
Objective: This study aimed to evaluate the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Methods: A comprehensive search using PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, and CNKI databases was conducted to extract relevant data based on predefined inclusion criteria. RevMan5.2 was applied to analyze and compare the effect of surgical versus nonsurgical treatment on mortality in patients with encapsulating peritoneal sclerosis who underwent peritoneal dialysis. Results: A total of 7 studies involving 70 surgical and 57 nonsurgical patients were included, with 61.4% females and 38.6% males. Among them, 69 were Asian and 58 were European patients, with 37.7% and 75.9% of Asian and European patients accepting surgical treatment, respectively. Pooled data analysis indicated that surgical treatment was associated with significantly lower mortality than nonsurgical treatment in patients with encapsulating peritoneal sclerosis (odds ratio = 0.25, 95% confidence interval: 0.11–0.57, Z = 3.29; P = 0.001). Subgroup analysis revealed that Asian patients who accepted surgical treatment had significantly lower mortality than those receiving nonsurgical treatment (odds ratio = 0.19, 95% confidence interval: 0.06–0.57, Z = 2.93; P = 0.003), whereas no significant difference was observed in mortality between surgical and nonsurgical treatments in European patients (odds ratio = 0.38, 95% confidence interval: 0.10–1.41, Z = 1.45; P = 0.15). Conclusions: Surgical treatment was associated with reduced mortality in patients with encapsulating peritoneal sclerosis compared with nonsurgical treatment; however, this benefit was more significant in Asian patients than in European patients.
- Open Access
- 24 February 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (2)
Carcinoma of the ampulla of Vater with membranous nephropathy: a case report
Nephrotic syndrome can occur secondary to malignancy, and its resolution is sometimes observed following tumor resection. We herein report the case of a 67-year-old Asian man who presented with membranous nephropathy associated with carcinoma of the ampulla of Vater. The patient initially presented with edema, hypoalbuminemia, and significant proteinuria with positive PLA2R antibody. Following surgical removal of the tumor, his urinary protein levels normalized, his serum albumin returned to normal, and the nephrotic syndrome achieved complete remission. This case underscores the importance of screening for secondary causes, such as malignancies, in patients with nephrotic syndrome. For those with malignancy-associated nephrotic syndrome, prompt and targeted treatment of the underlying tumor is critical to avoid missing the window for surgical intervention. This report aims to provide insights into the diagnosis and management of tumor-associated nephrotic syndrome, contributing to a better understanding of this rare clinical entity.
- 24 February 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (2)
Open AccessCarcinoma of the ampulla of Vater with membranous nephropathy: a case report
Nephrotic syndrome can occur secondary to malignancy, and its resolution is sometimes observed following tumor resection. We herein report the case of a 67-year-old Asian man who presented with membranous nephropathy associated with carcinoma of the ampulla of Vater. The patient initially presented with edema, hypoalbuminemia, and significant proteinuria with positive PLA2R antibody. Following surgical removal of the tumor, his urinary protein levels normalized, his serum albumin returned to normal, and the nephrotic syndrome achieved complete remission. This case underscores the importance of screening for secondary causes, such as malignancies, in patients with nephrotic syndrome. For those with malignancy-associated nephrotic syndrome, prompt and targeted treatment of the underlying tumor is critical to avoid missing the window for surgical intervention. This report aims to provide insights into the diagnosis and management of tumor-associated nephrotic syndrome, contributing to a better understanding of this rare clinical entity.
- 31 July 2019
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 22 (5) , 772-781
Orphan nuclear receptor COUP-TFII is an oncogenic gene in renal cell carcinoma
Background Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) may be an oncogenic gene in renal cell carcinoma (RCC). However, the direct association between COUP-TFII expression and patient survival has not been investigated in patients with RCC, and the molecular oncogenesis of COUP-TFII in RCC remains unclear. Methods The mRNA expression levels of COUP-TFII in the tumors of 283 patients with RCC were determined by RT-qPCR. The remaining 266 patients were categorized into low- and high-expression groups according to the cut off value generated by receiver operating curve (ROC) analysis. The function of COUP-TFII in RCC cells was tested by knockdown experiments in vitro. Results In the present study, it was revealed that the mRNA expression levels of COUP-TFII were significantly higher in tumors compared with those in adjacent non-cancerous tissues, and that the overexpression of COUP-TFII was strongly associated with poor patient survival. It was further demonstrated that knockdown of COUP-TFII suppressed proliferation, and induced apoptosis and cell cycle arrest in RCC cells in vitro. This also resulted in the activation of the mitochondria-mediated apoptosis pathway, impaired migration and invasion of RCC cells through epithelial–mesenchymal transition in vitro, and suppressed tumor growth in vivo. In addition, it was revealed that the induction of cell migration and invasion by COUP-TFII was mediated, at least in part, by integrin subunit β1. Conclusions In summary, the present study indicated that COUP-TFII is an oncogenic gene in RCC, and a potential therapeutic target for the treatment of the disease.
- 31 July 2019
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 22 (5) , 772-781
Orphan nuclear receptor COUP-TFII is an oncogenic gene in renal cell carcinoma
Background Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) may be an oncogenic gene in renal cell carcinoma (RCC). However, the direct association between COUP-TFII expression and patient survival has not been investigated in patients with RCC, and the molecular oncogenesis of COUP-TFII in RCC remains unclear. Methods The mRNA expression levels of COUP-TFII in the tumors of 283 patients with RCC were determined by RT-qPCR. The remaining 266 patients were categorized into low- and high-expression groups according to the cut off value generated by receiver operating curve (ROC) analysis. The function of COUP-TFII in RCC cells was tested by knockdown experiments in vitro. Results In the present study, it was revealed that the mRNA expression levels of COUP-TFII were significantly higher in tumors compared with those in adjacent non-cancerous tissues, and that the overexpression of COUP-TFII was strongly associated with poor patient survival. It was further demonstrated that knockdown of COUP-TFII suppressed proliferation, and induced apoptosis and cell cycle arrest in RCC cells in vitro. This also resulted in the activation of the mitochondria-mediated apoptosis pathway, impaired migration and invasion of RCC cells through epithelial–mesenchymal transition in vitro, and suppressed tumor growth in vivo. In addition, it was revealed that the induction of cell migration and invasion by COUP-TFII was mediated, at least in part, by integrin subunit β1. Conclusions In summary, the present study indicated that COUP-TFII is an oncogenic gene in RCC, and a potential therapeutic target for the treatment of the disease.
- 16 February 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (7) , 11490-11497
The skewed frequency of B‐cell subpopulation CD19+CD24hiCD38hi cells in peripheral blood mononuclear cells is correlated with the elevated serum sCD40L in patients with active systemic lupus erythematosus
CD19+CD24hiCD38hi cells play an essential role in maintaining immune homeostasis. CD40 signaling is involved in regulating the induction and function of CD19+CD24hiCD38hi cells. Changes in B‐cell subpopulations and CD19+CD24hiCD38hi cells have been observed in systemic lupus erythematosus (SLE) patients. Whether changes in the B‐cell subpopulation are related to the aberrant CD40 signaling in SLE patients remains unclear. In this study, we examined changes in the levels of CD19+CD24hiCD38hi cells and CD19+CD24hiCD38low cells in peripheral blood mononuclear cells and the serum level of soluble CD40 ligand (sCD40L) in 30 patients with SLE. Through routine biochemical assays and flow cytometry assay, we found that (1) the CD19+CD24hiCD38hi cell subset was upregulated in SLE patients compared to that in healthy controls (HCs) (P < 0.05); (2) the CD19+CD24hiCD38low cell subset was downregulated in SLE patients compared with that in HCs; and (3) CD38 expression was positively correlated with SLE manifestations and the serum sCD40L level (P < 0.05). In conclusion, the relative level of Bregs is significantly higher in SLE patients than in HCs and is positively correlated with disease activity and sCD40L level.
- 16 February 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (7) , 11490-11497
The skewed frequency of B‐cell subpopulation CD19+CD24hiCD38hi cells in peripheral blood mononuclear cells is correlated with the elevated serum sCD40L in patients with active systemic lupus erythematosus
CD19+CD24hiCD38hi cells play an essential role in maintaining immune homeostasis. CD40 signaling is involved in regulating the induction and function of CD19+CD24hiCD38hi cells. Changes in B‐cell subpopulations and CD19+CD24hiCD38hi cells have been observed in systemic lupus erythematosus (SLE) patients. Whether changes in the B‐cell subpopulation are related to the aberrant CD40 signaling in SLE patients remains unclear. In this study, we examined changes in the levels of CD19+CD24hiCD38hi cells and CD19+CD24hiCD38low cells in peripheral blood mononuclear cells and the serum level of soluble CD40 ligand (sCD40L) in 30 patients with SLE. Through routine biochemical assays and flow cytometry assay, we found that (1) the CD19+CD24hiCD38hi cell subset was upregulated in SLE patients compared to that in healthy controls (HCs) (P < 0.05); (2) the CD19+CD24hiCD38low cell subset was downregulated in SLE patients compared with that in HCs; and (3) CD38 expression was positively correlated with SLE manifestations and the serum sCD40L level (P < 0.05). In conclusion, the relative level of Bregs is significantly higher in SLE patients than in HCs and is positively correlated with disease activity and sCD40L level.
- 17 June 2013
- Published by Springer Nature in Current Medical Science
- Vol. 33 (3) , 368-374
Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats
This study investigated the effects of benazepril administered in the morning or evening on the diurnal variation of renin-angiotensin-aldosterone system (RAAS) and clock genes in the kidney. The male Wistar rat models of 5/6 subtotal nephrectomy (STNx) were established. Animals were randomly divided into 4 groups: sham STNx group (control), STNx group, morning benazepril group (MB) and evening benazepril group (EB). Benazepril was intragastrically administered at a dose of 10 mg/kg/day at 07:00 and 19:00 in the MB group and EB group respectively for 12 weeks. All the animals were synchronized to the light:dark cycle of 12:12 for 12 weeks. Systolic blood pressure (SBP), 24-h urinary protein excretion and renal function were measured at 11 weeks. Blood samples and kidneys were collected every 4 h throughout a day to detect the expression pattern of renin activity (RA), angiotensin II (AngII) and aldosterone (Ald) by radioimmunoassay (RIA) and the mRNA expression profile of clock genes (bmal1, dbp and per2) by real-time PCR at 12 weeks. Our results showed that no significant differences were noted in the SBP, 24-h urine protein excretion and renal function between the MB and EB groups. There were no significant differences in average Ald and RA content of a day between the MB group and EB group. The expression peak of bmal1 mRNA was phase-delayed by 4 to 8 h, and the diurnal variation of per2 and dbp mRNA diminished in the MB and EB groups compared with the control and STNx groups. It was concluded when the similar SBP reduction, RAAS inhibition and clock gene profile were achieved with optimal dose of benazepril, morning versus evening dosing of benazepril has the same renoprotection effects.
- 17 June 2013
- Published by Springer Nature in Current Medical Science
- Vol. 33 (3) , 368-374
Effects of chronotherapy of benazepril on the diurnal profile of RAAS and clock genes in the kidney of 5/6 nephrectomy rats
This study investigated the effects of benazepril administered in the morning or evening on the diurnal variation of renin-angiotensin-aldosterone system (RAAS) and clock genes in the kidney. The male Wistar rat models of 5/6 subtotal nephrectomy (STNx) were established. Animals were randomly divided into 4 groups: sham STNx group (control), STNx group, morning benazepril group (MB) and evening benazepril group (EB). Benazepril was intragastrically administered at a dose of 10 mg/kg/day at 07:00 and 19:00 in the MB group and EB group respectively for 12 weeks. All the animals were synchronized to the light:dark cycle of 12:12 for 12 weeks. Systolic blood pressure (SBP), 24-h urinary protein excretion and renal function were measured at 11 weeks. Blood samples and kidneys were collected every 4 h throughout a day to detect the expression pattern of renin activity (RA), angiotensin II (AngII) and aldosterone (Ald) by radioimmunoassay (RIA) and the mRNA expression profile of clock genes (bmal1, dbp and per2) by real-time PCR at 12 weeks. Our results showed that no significant differences were noted in the SBP, 24-h urine protein excretion and renal function between the MB and EB groups. There were no significant differences in average Ald and RA content of a day between the MB group and EB group. The expression peak of bmal1 mRNA was phase-delayed by 4 to 8 h, and the diurnal variation of per2 and dbp mRNA diminished in the MB and EB groups compared with the control and STNx groups. It was concluded when the similar SBP reduction, RAAS inhibition and clock gene profile were achieved with optimal dose of benazepril, morning versus evening dosing of benazepril has the same renoprotection effects.